 |
Publications |
|
Viral vectors as vaccine platforms: deployment in sight. Christine S Rollier, Arturo Reyes-Sandoval, Matthew G Cottingham, Katie Ewer and Adrian VS Hill (2011). Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology 23:377–382 |
|
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest v... Riezebos-Brilman A, Walczak M, Regts J, Kamps G, Rots M, Dontje B, Haisma HJ, Wilschut J and Daemen T. (2007) A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and recombinant adenovirus. Gene Therapy, 14(24):1695-704. |
|
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy Riezebos-Brilman A, de Mare A, Bungener L, Huckriede A, Wilschut J and Daemen T. (2006) Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J. Clin. Virology, 35: 233-243. |
|
Induction of human papilloma virus type 16 E7 specific T cell responses by local inva... Visser JTJ, van Baarle D, Hoogeboom B-N, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Miedema F, Bungener LB, de Vries-Idema J. Nijman HW, Daemen T and Van der Zee AGE. (2006) Induction of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int. J. Cancer 118(10):2529-2537. |
|
Immunization of Human Papilloma virus E6/E7-transgenic mice with a recombinant Semlik... Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J and Daemen T. (2005) Immunization of Human Papilloma virus E6/E7-transgenic mice with a recombinant Semliki Forest virus vector breaks immune tolerance for the E6/E7 antigens. Gene Therapy, 12, 1410-1414. |
|
Superior therapeutic efficacy of alphavirus-mediated immunization against human papil... Daemen T, Riezebos-Brilman A, Regts J, Dontje B van der Zee AGJ, and Wilschut J. (2004) Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumor model: effects of the route of immunization. Antiviral Therapy, 9, 733-742. |
|
Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki... Huckriede A, Bungener L, Holtrop M, Idema J, Waarts BL, Daemen T and Wilschut J. (2004) Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: Evidence for cross-priming. Vaccine, 22, 1104-1113. |
|
Eradication of established HPV16-transformed tumors after immunisation with recombina... Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B and Wilschut J (2003) Eradication of established HPV16-transformed tumors after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine, 21, 1082-1088. |
|
Immunization strategy against cervical cancer involving an alphavirus vector expressi... Daemen T, Regts J, Holtrop M and Wilschut J. (2002) Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 9, 85-94. |
|
Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte ... Daemen T, Pries F, Bungener L, Kraak M, Regts J and Wilschut J. (2000) Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Therapy 7, 1859-1866. |
|
Two-helper RNA system for production of recombinant Semliki forest virus particles Smerdou C, Liljeström P.Two-helper RNA system for production of recombinant Semliki forest virus particles.J Virol. 1999, 73(2):1092-1098 |
| |
|
|
|
